449 related articles for article (PubMed ID: 16472600)
21. Lessons from the toxic bile concept for the pathogenesis and treatment of cholestatic liver diseases.
Trauner M; Fickert P; Halilbasic E; Moustafa T
Wien Med Wochenschr; 2008; 158(19-20):542-8. PubMed ID: 18998069
[TBL] [Abstract][Full Text] [Related]
22. High dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis is safe and effective.
Cullen SN; Rust C; Fleming K; Edwards C; Beuers U; Chapman RW
J Hepatol; 2008 May; 48(5):792-800. PubMed ID: 18314215
[TBL] [Abstract][Full Text] [Related]
23. Gene expression profiles reflect sclerosing cholangitis activity in abcb4 (-/-) mice.
Nakken KE; Nygard S; Haaland TK; Berge KE; Ødegaard A; Labori KJ; Raeder MG
Scand J Gastroenterol; 2009; 44(2):211-8. PubMed ID: 18785065
[TBL] [Abstract][Full Text] [Related]
24. Bile salt toxicity aggravates cold ischemic injury of bile ducts after liver transplantation in Mdr2+/- mice.
Hoekstra H; Porte RJ; Tian Y; Jochum W; Stieger B; Moritz W; Slooff MJ; Graf R; Clavien PA
Hepatology; 2006 May; 43(5):1022-31. PubMed ID: 16628673
[TBL] [Abstract][Full Text] [Related]
25. Changes of the hepatic proteome in murine models for toxically induced fibrogenesis and sclerosing cholangitis.
Henkel C; Roderfeld M; Weiskirchen R; Berres ML; Hillebrandt S; Lammert F; Meyer HE; Stühler K; Graf J; Roeb E
Proteomics; 2006 Dec; 6(24):6538-48. PubMed ID: 17109383
[TBL] [Abstract][Full Text] [Related]
26. Ursodeoxycholic acid in the treatment of primary sclerosing cholangitis.
Stiehl A
Ital J Gastroenterol; 1996 Apr; 28(3):178-80. PubMed ID: 8789831
[TBL] [Abstract][Full Text] [Related]
27. Inhibition of intestinal bile acid absorption improves cholestatic liver and bile duct injury in a mouse model of sclerosing cholangitis.
Baghdasaryan A; Fuchs CD; Österreicher CH; Lemberger UJ; Halilbasic E; Påhlman I; Graffner H; Krones E; Fickert P; Wahlström A; Ståhlman M; Paumgartner G; Marschall HU; Trauner M
J Hepatol; 2016 Mar; 64(3):674-81. PubMed ID: 26529078
[TBL] [Abstract][Full Text] [Related]
28. Clinical trial: modulation of human placental multidrug resistance proteins in cholestasis of pregnancy by ursodeoxycholic acid.
Azzaroli F; Mennone A; Feletti V; Simoni P; Baglivo E; Montagnani M; Rizzo N; Pelusi G; DE Aloysio D; Lodato F; Festi D; Colecchia A; Roda E; Boyer JL; Mazzella G
Aliment Pharmacol Ther; 2007 Oct; 26(8):1139-46. PubMed ID: 17894656
[TBL] [Abstract][Full Text] [Related]
29. Activation of the cholehepatic shunt as a potential therapy for primary sclerosing cholangitis.
Glaser SS; Alpini G
Hepatology; 2009 Jun; 49(6):1795-7. PubMed ID: 19475683
[No Abstract] [Full Text] [Related]
30. NorUrsodeoxycholic acid ameliorates cholemic nephropathy in bile duct ligated mice.
Krones E; Eller K; Pollheimer MJ; Racedo S; Kirsch AH; Frauscher B; Wahlström A; Ståhlman M; Trauner M; Grahammer F; Huber TB; Wagner K; Rosenkranz AR; Marschall HU; Fickert P
J Hepatol; 2017 Jul; 67(1):110-119. PubMed ID: 28242240
[TBL] [Abstract][Full Text] [Related]
31. Asymptomatic primary sclerosing cholangitis treated with ursodeoxycholic acid.
Hayashi H; Higuchi T; Ichimiya H; Hishida N; Sakamoto N
Gastroenterology; 1990 Aug; 99(2):533-5. PubMed ID: 2365199
[TBL] [Abstract][Full Text] [Related]
32. The impact of ursodeoxycholic acid on cancer, dysplasia and mortality in ulcerative colitis patients with primary sclerosing cholangitis.
Wolf JM; Rybicki LA; Lashner BA
Aliment Pharmacol Ther; 2005 Nov; 22(9):783-8. PubMed ID: 16225486
[TBL] [Abstract][Full Text] [Related]
33. Tetrahydroxylated bile acids improve cholestatic liver and bile duct injury in the Mdr2
Fuchs CD; Dixon ED; Hendrikx T; Mlitz V; Wahlström A; Ståhlman M; Scharnagl H; Stojakovic T; Binder CJ; Marschall HU; Trauner M
Hepatol Commun; 2022 Sep; 6(9):2368-2378. PubMed ID: 35691019
[TBL] [Abstract][Full Text] [Related]
34. Monoacylglycerol Lipase Inhibition Protects From Liver Injury in Mouse Models of Sclerosing Cholangitis.
Tardelli M; Bruschi FV; Fuchs CD; Claudel T; Auer N; Kunczer V; Baumgartner M; A H O Ronda O; Verkade HJ; Stojakovic T; Scharnagl H; Habib A; Zimmermann R; Lotersztajn S; Trauner M
Hepatology; 2020 May; 71(5):1750-1765. PubMed ID: 31505038
[TBL] [Abstract][Full Text] [Related]
35. Multiple inflammatory-, tissue remodelling- and fibrosis genes are differentially transcribed in the livers of Abcb4 (-/ - ) mice harbouring chronic cholangitis.
Nakken KE; Nygård S; Haaland T; Berge KE; Arnkvaern K; Ødegaard A; Labori KJ; Raeder MG
Scand J Gastroenterol; 2007 Oct; 42(10):1245-55. PubMed ID: 17852852
[TBL] [Abstract][Full Text] [Related]
36. Integrin alphavbeta6 is a marker of the progression of biliary and portal liver fibrosis and a novel target for antifibrotic therapies.
Popov Y; Patsenker E; Stickel F; Zaks J; Bhaskar KR; Niedobitek G; Kolb A; Friess H; Schuppan D
J Hepatol; 2008 Mar; 48(3):453-64. PubMed ID: 18221819
[TBL] [Abstract][Full Text] [Related]
37. New therapeutical indications of ursodeoxycholic acid.
Copaci I; Micu L; Iliescu L; Voiculescu M
Rom J Gastroenterol; 2005 Sep; 14(3):259-66. PubMed ID: 16200237
[TBL] [Abstract][Full Text] [Related]
38. Primary sclerosing cholangitis.
Geonzon-Gonzales MR
Gastroenterol Nurs; 2007; 30(2):102-5; quiz 105-7. PubMed ID: 17440311
[TBL] [Abstract][Full Text] [Related]
39. [Drug therapy of cholestatic hepatopathies].
Leuschner U
Schweiz Rundsch Med Prax; 1992 Aug; 81(34):983-4. PubMed ID: 1529191
[TBL] [Abstract][Full Text] [Related]
40. The current status of ursodeoxycholate in the treatment of chronic cholestatic liver disease.
Luketic VA; Sanyal AJ
Gastroenterologist; 1994 Mar; 2(1):74-9. PubMed ID: 8055235
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
